Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
1.015
-0.155 (-13.25%)
At close: Aug 14, 2026, 4:00 PM EDT
1.010
-0.005 (-0.49%)
After-hours: Aug 14, 2026, 7:51 PM EDT

Tempest Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
15.4213.9713.5511.6612.119.82
Research & Development
3.0412.6128.4817.522.5317.17
Operating Expenses
18.4626.5842.0329.1634.6426.99
Operating Income
-18.46-26.58-42.03-29.16-34.64-26.99
Interest Expense
--0.21-1.32-1.45-1.62-1.28
Interest & Investment Income
0.170.521.51.120.55-
Other Non Operating Income (Expenses)
------0.03
Pretax Income
-40.47-26.26-41.84-29.49-35.71-28.3
Net Income
-40.47-26.26-41.84-29.49-35.71-28.3
Net Income to Common
-40.47-26.26-41.84-29.49-35.71-28.3
Net Income Growth
------
Shares Outstanding (Basic)
942110
Shares Outstanding (Diluted)
942110
Shares Change
186.97%93.35%80.99%33.49%204.70%709.63%
EPS (Basic)
-4.56-6.33-19.50-24.87-40.20-97.07
EPS (Diluted)
-4.56-6.33-19.50-24.87-40.20-97.07
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-20.73-26.82-33.46-27.53-31.63-26.09
Free Cash Flow Per Share
-2.33-6.46-15.59-23.21-35.61-89.49
EBITDA
-18.21-26.31-41.64-28.78-34-26.61
D&A For EBITDA
0.250.270.390.380.640.37
EBIT
-18.46-26.58-42.03-29.16-34.64-26.99
SEC Filings: 10-K · 10-Q